Search
 
 
NEWS
 
Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform - Business Wire
Phillips Evaluates Second-Line Therapy Options for R/R DLBCL - Targeted Oncology
FDA Approval Sought for Talquetamab for the Treatment of R/R Multiple Myeloma - Targeted Oncology
An Overview of Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) - Targeted Oncology